SAN

90.9

-1.98%↓

SRT3

231.8

+1.22%↑

BIM

117.6

+0.86%↑

ORNBV.FI

54.35

-0.91%↓

GXI

62

+2.31%↑

SAN

90.9

-1.98%↓

SRT3

231.8

+1.22%↑

BIM

117.6

+0.86%↑

ORNBV.FI

54.35

-0.91%↓

GXI

62

+2.31%↑

SAN

90.9

-1.98%↓

SRT3

231.8

+1.22%↑

BIM

117.6

+0.86%↑

ORNBV.FI

54.35

-0.91%↓

GXI

62

+2.31%↑

SAN

90.9

-1.98%↓

SRT3

231.8

+1.22%↑

BIM

117.6

+0.86%↑

ORNBV.FI

54.35

-0.91%↓

GXI

62

+2.31%↑

SAN

90.9

-1.98%↓

SRT3

231.8

+1.22%↑

BIM

117.6

+0.86%↑

ORNBV.FI

54.35

-0.91%↓

GXI

62

+2.31%↑

Search

UCB SA

Geschlossen

BrancheGesundheitswesen

157.65 2.24

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

145.65

Max

157.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

649M

857M

Verkäufe

570M

3.4B

KGV

Branchendurchschnitt

29.407

54.379

EPS

2.09

Dividendenrendite

0.86

Gewinnspanne

25.498

Angestellte

9,052

EBITDA

704M

1.3B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.86%

2.55%

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-5.1B

31B

Vorheriger Eröffnungskurs

155.41

Vorheriger Schlusskurs

157.65

Nachrichtenstimmung

By Acuity

50%

50%

198 / 382 Ranking in Healthcare

UCB SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

12. Mai 2025, 22:34 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. Mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12. Mai 2025, 23:46 UTC

Market Talk

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12. Mai 2025, 23:34 UTC

Market Talk

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12. Mai 2025, 23:21 UTC

Market Talk

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12. Mai 2025, 22:54 UTC

Market Talk

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12. Mai 2025, 22:43 UTC

Ergebnisse

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12. Mai 2025, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12. Mai 2025, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12. Mai 2025, 22:07 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Australia Retail Electricity Business to AGL

12. Mai 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12. Mai 2025, 22:06 UTC

Akquisitionen, Fusionen, Übernahmen

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12. Mai 2025, 22:05 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12. Mai 2025, 22:04 UTC

Akquisitionen, Fusionen, Übernahmen

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12. Mai 2025, 21:15 UTC

Top News

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q Rev $2.65B >CSU.T

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q Net $115M >CSU.T

12. Mai 2025, 21:01 UTC

Ergebnisse

Constellation Software 1Q EPS $5.44 >CSU.T

12. Mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

12. Mai 2025, 20:50 UTC

Market Talk
Ergebnisse

Basic Materials Roundup: Market Talk

12. Mai 2025, 20:44 UTC

Top News

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12. Mai 2025, 20:31 UTC

Top News

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12. Mai 2025, 20:24 UTC

Ergebnisse

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12. Mai 2025, 20:24 UTC

Ergebnisse

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12. Mai 2025, 20:24 UTC

Top News

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12. Mai 2025, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12. Mai 2025, 20:15 UTC

Ergebnisse

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12. Mai 2025, 20:10 UTC

Ergebnisse

Blink Charging 1Q Rev $20.8M >BLNK

Peer-Vergleich

Kursveränderung

UCB SA Prognose

Kursziel

By TipRanks

19.23% Vorteil

12-Monats-Prognose

Durchschnitt 94.86 EUR  19.23%

Hoch 125 EUR

Tief 74 EUR

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für UCB SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

7 ratings

4

Buy

1

Halten

2

Sell

Stimmung

By Acuity

198 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.